Scientists Uncover Why Cancer Drugs Fail
Why it matters: Understanding BRD2 and BRD4's distinct roles could lead to more precise cancer drug design for patients.
- BET inhibitors, a class of cancer drugs, have shown limited success in real patients despite promising lab experiments (Max Planck Institute of Immunobiology and Epigenetics).
- New research reveals that the assumption of similar behavior among all BET proteins is incorrect, specifically for BRD2 and BRD4 (Max Planck Institute of Immunobiology and Epigenetics).
- BRD2 functions as a 'stage manager,' preparing genes for activation by assembling molecular components (Max Planck Institute of Immunobiology and Epigenetics).
- BRD4 is involved later, triggering the final step of gene activation by releasing RNA Polymerase II (Max Planck Institute of Immunobiology and Epigenetics).
- Current BET drugs may be disrupting gene activation unpredictably by blocking both BRD2 and BRD4 simultaneously (Max Planck Institute of Immunobiology and Epigenetics).
Promising cancer drugs called BET inhibitors have consistently underperformed in patients despite strong lab results, a mystery now potentially solved by researchers at the Max Planck Institute of Immunobiology and Epigenetics. They discovered that two key proteins, BRD2 and BRD4, previously thought to be interchangeable, actually play distinct roles in gene activation, with BRD2 acting as a 'stage manager' for preparation and BRD4 triggering the final 'on' switch.
